Get the Stockscreener App
89.62
0.54%
0.48
After Hours:
88.00
-1.62
-1.81%
Bright Minds Biosciences Inc stock is traded at $89.62, with a volume of 107.49K.
It is up +0.54% in the last 24 hours and up +24.47% over the past month.
Bright Minds Biosciences Inc is focused on developing novel, transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult-to-treat disorders such as resistant epilepsy, treatment-resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.
See More
Previous Close:
$89.14
Open:
$88.68
24h Volume:
107.49K
Relative Volume:
0.80
Market Cap:
$877.13M
Revenue:
-
Net Income/Loss:
$-14.23M
P/E Ratio:
-46.21
EPS:
-1.9396
Net Cash Flow:
$-9.44M
1W Performance:
+8.29%
1M Performance:
+24.47%
6M Performance:
+31.72%
1Y Performance:
+176.52%
1-Day Range:
$87.51
$90.28
1-Week Range:
$79.86
$90.36
52-Week Range:
$23.18
$123.75
Bright Minds Biosciences Inc Stock (DRUG) Company Profile
Name
Bright Minds Biosciences Inc
Sector
Industry
Phone
-
Address
-
Compare DRUG vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DRUG
Bright Minds Biosciences Inc
|
89.62 | 872.43M | 0 | -14.23M | -9.44M | -1.9396 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Bright Minds Biosciences Inc Stock (DRUG) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-08-25 | Initiated | BTIG Research | Buy |
| May-13-25 | Initiated | TD Cowen | Buy |
| May-07-25 | Initiated | Chardan Capital Markets | Buy |
| Jan-23-25 | Initiated | Piper Sandler | Overweight |
| Jan-10-25 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-10-25 | Initiated | H.C. Wainwright | Buy |
| Nov-26-24 | Initiated | Robert W. Baird | Outperform |
View All
Bright Minds Biosciences Inc Stock (DRUG) Latest News
Bright Minds Biosciences (NASDAQ:DRUG) Earns Buy Rating from Analysts at Jefferies Financial Group - MarketBeat
Jefferies initiates Bright Minds stock with buy on epilepsy drug By Investing.com - Investing.com South Africa
Jefferies initiates Bright Minds stock with buy on epilepsy drug - Investing.com
Total debt per share of Bright Minds Biosciences Inc. – NEO:DRUG - TradingView
Certain RSUs of Bright Minds Biosciences Inc. are subject to a Lock-Up Agreement Ending on 8-APR-2026. - marketscreener.com
Certain Options of Bright Minds Biosciences Inc. are subject to a Lock-Up Agreement Ending on 8-APR-2026. - marketscreener.com
7,787,161 Common Shares of Bright Minds Biosciences Inc. are subject to a Lock-Up Agreement Ending on 8-APR-2026. - marketscreener.com
Bright Minds Biosciences (NASDAQ:DRUG) Shares Gap UpHere's Why - MarketBeat
Pullback Watch: Is Bright Minds Biosciences Inc a cyclical or defensive stockRecession Risk & Target Return Focused Stock Picks - baoquankhu1.vn
Bright Minds Biosciences (NASDAQ:DRUG) Trading 7.4% HigherWhat's Next? - MarketBeat
Sentiment Watch: What is PROVs 5 year growth outlookWeekly Profit Recap & Proven Capital Preservation Methods - baoquankhu1.vn
Responsive Playbooks and the DRUG Inflection - Stock Traders Daily
Bright Minds announces ATM offering up to $100 million - MSN
Bright Minds Biosciences Inc. (DRUG.NE) interactive stock chart - Yahoo Finance UK
Bright Minds Biosciences Inc. (DRUG.NE) Stock Forum & Discussion - Yahoo! Finance Canada
Bright Minds Biosciences Inc Live Share Prices and Trades. DRUG.US Live Streaming Share Prices. - London South East
Swing Trade: Whats the profit margin of WB PRCCLTrade Exit Report & Community Verified Watchlist Alerts - baoquankhu1.vn
Bright Minds Biosciences (NASDAQ:DRUG) Given Buy Rating at BTIG Research - Defense World
Bright Minds Biosciences (NASDAQ:DRUG) Earns Buy Rating from BTIG Research - MarketBeat
BTIG reiterates Bright Minds Biosciences stock rating on seizure treatment potential - Investing.com India
What is the probability of success for Bright Minds Biosciences Inc (DRUG)’s lead drug candidate? - msn.com
Bright Minds Biosciences Inc. (NASDAQ:DRUG) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Bright Minds Biosciences Inc. (NASDAQ:DRUG) Receives Average Recommendation of “Moderate Buy” from Brokerages - defenseworld.net
Hedge Fund Bets: How much upside does Bright Minds Biosciences Inc have2026 Macro Moves & Weekly Top Stock Performers List - baoquankhu1.vn
What Is the Probability of Success for Bright Minds Biosciences Inc (DRUG)’s Lead Drug Candidate? - insidermonkey.com
Understanding the Setup: (DRUG) and Scalable Risk - Stock Traders Daily
Bright Minds Biosciences (NASDAQ:DRUG) Raised to "Hold" at Wall Street Zen - MarketBeat
Risk Off: Is PMTPRC showing insider buying2026 Decliners & Trade Opportunity Analysis Reports - baoquankhu1.vn
Pullback Watch: Is Bright Minds Biosciences Inc undervalued by DCF analysis2026 Price Momentum & Expert Approved Momentum Ideas - baoquankhu1.vn
303,685 Shares in Bright Minds Biosciences Inc. $DRUG Acquired by Braidwell LP - MarketBeat
The Technical Signals Behind (DRUG) That Institutions Follow - Stock Traders Daily
Bright Minds gains on mid-stage trial win for lead asset - MSN
Is Bright Minds Biosciences Inc. stock supported by innovation pipelineAnalyst Upgrade & Low Risk High Reward Ideas - Naître et grandir
Risk Report: Is Bright Minds Biosciences Inc a cyclical or defensive stock2025 Retail Activity & Daily Volume Surge Signals - baoquankhu1.vn
Bright Minds Biosciences sets January 6 webcast for BMB-101 phase 2 topline results in drug-resistant absence seizures - MSN
Market Outlook: What is the Moat Score of Bright Minds Biosciences IncJuly 2025 Breakouts & Fast Moving Stock Trade Plans - baoquankhu1.vn
HC Wainwright Has Bullish Forecast for DRUG Q2 Earnings - MarketBeat
HC Wainwright Raises Bright Minds Biosciences (NASDAQ:DRUG) Price Target to $145.00 - Defense World
Bright Minds stock price target raised to $145 by H.C. Wainwright on trial data - Investing.com
Bright Minds Biosciences (NASDAQ:DRUG) Stock Price Expected to Rise, HC Wainwright Analyst Says - MarketBeat
DRUG: HC Wainwright & Co. Raises Price Target to $145, Maintains Buy Rating | DRUG Stock News - GuruFocus
Bright Minds Biosciences Inc. (NASDAQ:DRUG) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Precision Trading with Bright Minds Biosciences Inc. (DRUG) Risk Zones - Stock Traders Daily
Bright Minds Biosciences (NASDAQ:DRUG) Downgraded to Sell Rating by Wall Street Zen - MarketBeat
DRUG Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Bright Minds Biosciences to Present at Upcoming Conferences - The Manila Times
Published on: 2026-02-24 23:01:51 - baoquankhu1.vn
Stock Report: What are Bright Minds Biosciences Incs recent SEC filings showingJuly 2025 Chart Watch & Detailed Earnings Play Alerts - baoquankhu1.vn
Baird lowers Bright Minds Biosciences Inc. (DRUG) price target to $126, maintains outperform rating ahead of upcoming trials - MSN
Technical Reactions to DRUG Trends in Macro Strategies - Stock Traders Daily
Baird Lowers Bright Minds Biosciences Inc. (DRUG) Price Target to $126, Maintains Outperform Rating Ahead of Upcoming Trials - Finviz
Bright Minds Biosciences Inc Stock (DRUG) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.69%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):